The Phase III NIAGARA study evaluating AstraZeneca's Imfinzi (durvalumab) for neoadjuvant and adjuvant cisplatin-eligible muscle-invasive bladder cancer (MIBC) results were …
This week on Pipeline Moves, we kick off by looking at Novo Nordisk’s completion of a Phase III trial of …
An effective clinical trial design is crucial for a successful clinical research programme as it helps in maintaining the accuracy, …
Digitalising clinical trials can improve accessibility and engagement for participants, as well as data collection and analytics. It has the …
Patient recruitment in clinical trials plays a key role with regards to planning and execution. With increasingly complex study protocols …
Patient recruitment in clinical trials plays a key role with regards to planning and execution. With increasingly complex study protocols …
Contract research organizations (CROs), also known as clinical research organizations, offer their technical expertise and development support across all phases …
Clinical data management companies support the process of data collection, validation, and preparation for statistical analysis for clinical trials. Efficient clinical …
A robust logistics and supply chain network is required to conduct all types of clinical trials ranging from small regional …
One of Ipsen’s flagship oncology assets Cabometyx (cabozantinib) will not be gaining an indication in prostate cancer outside the US …
Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company …
The pharmaceutical industry is undergoing a major transformation, as clinical trials become increasingly data heavy and digital-based. Traditional methods of data …
Interstitial lung diseases (ILDs) are a range of conditions characterized by inflammation (fibrosis) of the alveolar wall. One of the …
Natera has released new data from the GALAXY arm of its ongoing CIRCULATE-Japan trial showing the efficacy of its molecular …
Johnson & Johnson has reported a 49% overall response rate in a colorectal cancer study with RYBREVANT (amivantamab-vmjw), in combination …
